5,613 Halozyme Therapeutics, Inc. $HALO Shares Sold by Retirement Systems of Alabama

Posted by Brian Himes on Nov 11th, 2026

Retirement Systems of Alabama reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 346,841 shares of the biopharmaceutical company’s stock after selling 5,613 shares during the quarter. Retirement Systems of Alabama owned approximately 0.31% of Halozyme Therapeutics worth $38,291,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of HALO. Bank of America Corp DE purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $196,540,000. Congress Asset Management Co. boosted its holdings in shares of Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after buying an additional 1,052,509 shares during the last quarter. Royal London Asset Management Ltd. boosted its holdings in shares of Halozyme Therapeutics by 12.4% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after buying an additional 200,262 shares during the last quarter. Finally, First Trust Advisors LP grew its position in Halozyme Therapeutics by 46.5% during the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock valued at $95,804,000 after buying an additional 470,558 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $102.98 on Wednesday. The company has a market cap of $11.74 billion, a PE ratio of 26.20, a price-to-earnings-growth ratio of 0.39 and a beta of 0.92. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $134.00. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 13.50. The firm’s 50-day simple moving average is $115.07 and its two-hundred day simple moving average is $85.05.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The company’s quarterly revenue was up 39.1% on a year-over-year basis. During the same quarter last year, the business earned $1.72 earnings per share. Research analysts predict that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on HALO shares. TD Cowen raised their price objective on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Stifel Nicolaus set a $130.00 target price on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Morgan Stanley set a $109.00 price target on shares of Halozyme Therapeutics and gave the stock a “reduce” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $108.18.

View Our Latest Stock Report on Halozyme Therapeutics

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the transaction, the director owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 124,226 shares of company stock valued at $13,370,893. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.